Biomarker Capture Platform Articles & Analysis
13 news found
Bodyport, a biomarker-guided digital therapeutics company on a mission to address complex chronic conditions, announced today the appointment of Jim Pursley to the company’s board of directors. ...
Bodyport, the digital health company focused on the detection and management of heart disease, today announced that it has named Amit Rushi as Chief Commercial Officer (CCO) and Phyllis Whiteley as Chair of the Board of Directors. With this newly created role, Amit Rushi will serve as part of the executive team and prepare the organization for commercialization and growth. As Chair of the Board, ...
Bodyport, a digital therapeutics company on a mission to address complex chronic conditions, announced today that its noninvasive biomarker platform, the Bodyport Cardiac Scale™ received U.S. Food & Drug Administration (FDA) 510(k) clearance. ...
The Bodyport solution is designed to capture hemodynamic signals through the Cardiac Scale to power optimized interventions tailored to the patient. ...
I truly believe our simple, intuitive biomarker platform will be able to do just that,” Lipman said. “Bodyport’s growing clinical evidence and commitment to a robust clinical roadmap have the potential to help detect heart failure events accurately and catch them earlier from the comfort of the patient’s home. ...
The Alzheimer's Podcast is available on all major podcast platforms including Apple Podcasts, Google Podcasts, Amazon Music and Spotify, as well as HealthUnmuted.com. ...
Chadha will lead all clinical and medical affairs as the company continues to develop, validate, and commercialize its AI-driven digital biomarker platform. She will report directly to the Chief Executive Officer of Altoida, Travis Bond, and will serve on the Leadership team. ...
Joint research of biomarkers on platform technology of GI Innovation, GI-SMART™, and SpAC9 Pipeline, AI-powered biomarker discovery platform of CellKey Prediction of drug response on next-generation immuno-oncology, personalized cancer treatment effects… increasing reliability and efficiency of treatment GI Innovation, an innovative new drug development company, announced on ...
Joint research of biomarkers on platform technology of GI Innovation, GI-SMARTTM and SpAC9 Pipeline, AI-powered biomarker discovery platform of CellKey Prediction of drug response on next generation immuno-oncology, personalized cancer treatment effects… increasing Reliability and efficiency of treatment GI Innovation, a new innovative drug development company, announced on February ...
Specific Diagnostics today announced results from two studies conducted in the Paris Teaching Hospital System (Assistance Publique-Hôpitaux Paris, AP-HP), Europe’s largest hospital network, reporting performance of the Reveal rapid antibiotic susceptibility testing (AST) system. Both studies, which comprised approximately 225 samples in total, found the same levels of accuracy ...
Co-founders and biomedical engineers Corey Centen and Sarah Smith founded Bodyport to develop a novel biomarker platform that could detect early signs of cardiovascular disease, incorporating proprietary sensor technology into a bathroom scale form factor. ...
Digital biomarker awards support technology solutions for early detection of Alzheimer’s and related dementias Data platform enables researchers using digital tools to share their findings for benchmarking, analysis and use across research projects ADDF’s Diagnostics Accelerator has $50 million in commitments from leading philanthropists Leonard A. Lauder, Bill Gates, Jeff Bezos ...
Results of Joint Study Presented at the American Association for Clinical Chemistry Conference BOSTON & VACAVILLE, CALIFORNIA , April 19, 2005 – PerkinElmer Inc. (NYSE: PKI ), a leading provider of drug discovery, life science research, and analytical solutions and Predictive Diagnostics, Inc., a wholly owned subsidiary of Large Scale Biology Corporation (NASDAQ: LSBC), announced ...